Research programme: ribosomal S6 kinase inhibitors - Phoenix Molecular Designs
Latest Information Update: 28 Mar 2025
At a glance
- Originator Phoenix Molecular Designs
- Class Anti-inflammatories; Antineoplastics; Cardiovascular therapies; Small molecules
- Mechanism of Action Ribosomal protein S6 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Cardiovascular disorders; Inflammation
Most Recent Events
- 28 Mar 2025 No recent reports of development identified for research development in Cardiovascular-disorders in Canada
- 28 Mar 2025 No recent reports of development identified for research development in Inflammation in Canada
- 28 Feb 2021 No recent reports of development identified for research development in Cancer in Canada